----
Current ValuationThe current P/E ratio is 39.81, above the reasonable range, cheaper than 0.54% of the time in the past 5 years, and the industry ranks 46/257, the industry Median -1.07.
39.81xP/E
$266.17Stock price
$6.69Earnings per share
39.81xP/E
Stock price$266.17Earnings per share$6.69
Historical Valuation
P/E ratioTypical rangeMedian
- P/E ratio
- 23.12x
- Typical range
- 11.80x–27.12x
Peer P/E ratio Comparison
It displays how the company's P/E ratio compares to top companies within its industry.
03774111148
The industry median valuation is currently at or below 0 and may not serve as a meaningful benchmark.
Industry P/E ratio Comparison
This shows the distribution of companies by P/E ratio range and their projected earnings per share growth for the next fiscal year.
0x30x60x90x120x150x
| Name/Symbol | |||
|---|---|---|---|
JNJUSJohnson & Johnson | 39.81x | 38.06% | $640.75B |
PFEUSPfizer | 39.45x | 22.19% | $170.99B |
RDYUSDr Reddys Laboratories | 39.84x | 12.08% | $11.91B |
AMRXUSAmneal Pharmaceuticals | 41.01x | 122.71% | $6.45B |
IBOUSImpact BioMedical | 43.42x | -- | $34.35M |
Risk Warning
Timeframes using financial data from S&P Global. The feature provides key metrics such as price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S) ratios, and dividend yield. For reference only and does not constitute investment advice.
